CanSino: Absorbable Cell-Free Pertussis Combined Vaccine for Infants and Young Children Obtains Drug Registration Certificate

Kang Xinuo announced that the company has recently obtained the "Drug Registration Certificate" issued by the National Medical Products Administration for the infant adsorbed acellular pertussis combination vaccine. This vaccine is the first domestically marketed pertussis vaccine, with each pertussis antigen purified separately to ensure product quality stability. This certification is the first product in the company's pertussis vaccine product combination to obtain a registration certificate, which will help enrich and optimize the company's commercial product structure and enhance brand effects. Upon forming sales orders in the future, it is expected to have a certain positive impact on the company's performance. The company will actively promote product production, batch issuance, and market sales, but the specific time for market launch is uncertain.